Abstract

Tuberculosis is essentially a curable disease but inspite of a WHO approved DOTS therapy, it still continues to ravage mankind. This situation is exacerbated by long course of chemotherapy, increasing drug resistance and co-emergence with HIV. The TB drug pipeline remained stagnant for a long time with no new drug approved till FDA approval for Bedaquiline. This situation has now improved with a number of agents in pre-clinical and clinical development against M. tuberculosis. In this review, we are focusing on some of the newer drugs in discovery and preclinical development against M. tuberculosis.

Keywords: Clinical strains, drugs, MIC, Mycobacterium, pre-clinical development, tuberculosis.

Graphical Abstract